gemigliptin
Trade name: Zemiglo
Small moleculeexperimental
Gemigliptin (rINN), sold under the brand name Zemiglo, is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 inhibitor class of drugs. Glucose lowering effects of DPP-4 inhibitors are mainly mediated by GLP-1 and gastric inhibitory polypeptide (GIP) incretin hormones which are inactivated by DPP-4. — Wikipedia
Clinical trial activity
17 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
2
Phase 3
2
Phase 4
3
Earliest trial started Jan 15, 2016 (NCT03310749)
Timeline
Indications
Approved for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGemigliptin ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05737771 | Phase 1 | Jan 25, 2023 | Daewoong Pharmaceutical Co. LTD. |
| NCT05194592 | Phase 4 | Jan 7, 2022 | Wonju Christian Hospital |
| NCT05105698 | Phase 1 | Jan 1, 2022 | LG |
| NCT04544319 | Phase 1 | Oct 31, 2020 | LG, Seoul National University |
| NCT04317703 | Phase 1 | Jul 1, 2020 | LG, Mahidol University |
| NCT04255238 | Phase 3 | Jun 30, 2020 | LG |
| NCT05663736 | Phase 4 | Jan 1, 2020 | Seoul National University |
| NCT04070794 | Phase 1 | Nov 1, 2019 | LG, Mahidol University |
| NCT04050098 | Phase 1 | Nov 1, 2019 | LG, Mahidol University |
| NCT03864432 | Phase 1 | May 31, 2019 | LG, Shanghai Xuhui District Central Hospital |
| NCT03842267 | Phase 3 | May 30, 2019 | LG |
| NCT03867942 | Phase 1 | Mar 21, 2019 | LG, Seoul National University |
| NCT03565458 | Phase 1 | Apr 5, 2018 | Kangbuk Samsung Hospital, LG |
| NCT03355014 | Phase 1 | Dec 13, 2017 | LG |
| NCT03202563 | Phase 4 | Aug 9, 2017 | LG, Sungkyunkwan University |
| NCT04705506 | N/A | Feb 5, 2017 | Navamindradhiraj University, Vajira Hospital |
| NCT03310749 | Phase 1 | Jan 15, 2016 | LG, National Autonomous University of Mexico, Stendhal Americas, S.A. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LG | For profit | 13 | 12 | 3 | 2016 |
| Mahidol University | Academic/Hospital | 3 | 0 | 1 | 2019 |
| Seoul National University | Academic/Hospital | 3 | 1 | 2 | 2019 |
| Daewoong Pharmaceutical Co. LTD. | For profit | 1 | 1 | 1 | 2023 |
| Kangbuk Samsung Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Autonomous University of Mexico | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Navamindradhiraj University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Shanghai Xuhui District Central Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Stendhal Americas, S.A. | For profit | 1 | 1 | 1 | 2016 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Vajira Hospital | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Wonju Christian Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
12 organizations
Page 1 / 1